We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ELIMINATING CONFLICT-OF-INTEREST WAIVERS WILL THREATEN SYSTEM, SAYS FDA

ELIMINATING CONFLICT-OF-INTEREST WAIVERS WILL THREATEN SYSTEM, SAYS FDA

May 17, 2006

The FDA opposes lawmakers' efforts to limit the agency's ability to grant conflict-of-interest waivers for advisory committee members, arguing that such a move would undermine its ability to have the necessary expert advice needed to make drug policy, an agency official says.

Legislative proposals to limit advisory committee membership where financial and other conflicts of interest exist threaten the FDA's advisory committee system, Steven Galson, director of CDER, said. "The system is really under threat now" due to legislation that contains "extreme views" on how to define conflict of interest, he said at the Chemical Heritage Foundation's recent centennial conference in Philadelphia.

Lawmakers and activists have criticized the agency's advisory committee policies, arguing that too many members of these boards have financial ties to industry, potentially clouding their judgment.

One proposed legislative remedy is Rep. Maurice Hinchey's (D-N.Y.) amendment to the fiscal year 2007 Agriculture, Rural Development, FDA and Related Agencies Appropriations bill. The amendment would prohibit the FDA from granting waivers allowing doctors or scientists with conflicts of interest to serve on FDA advisory panels.

The amendment was included in the version of the bill that is currently pending on the House floor. The House is expected to consider the bill by the end of this week. If passed, the bill then would go the Senate.

But the solution is not as simple as Hinchey suggests, according to Galson. Because the agency's work is so important, there will always be controversy surrounding its decisions. Given such an environment, there will always be advisory committee recommendations that people criticize, he added. (http://www.fdanews.com/did/5_97/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing